Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ingelvac CircoFLEX is a veterinary vaccine indicated for the active immunization of pigs against porcine circovirus type 2 (PCV2). It is a single-dose, inactivated subunit vaccine containing the ORF2 protein of PCV2, produced using a baculovirus vector system. The vaccine is formulated as an aqueous suspension with ImpranFLEX, a proprietary polymer adjuvant that enhances immunogenicity without using oil-based components. Upon intramuscular administration, it induces an immune response that reduces viremia, lymphoid depletion, inflammation and colonization of lymphoid tissue associated with PCV2 infection. Onset of immunity occurs within two weeks post-vaccination and lasts at least four months[1][3][4][5]. The product is developed and manufactured by Boehringer Ingelheim Animal Health.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Ingelvac CircoFLEX.